Piscitelli Dominic's Form 4/A amendment
AmendedOric Pharmaceuticals, Inc. (ORIC) · filed Feb 17, 2023
- Accession no.
- 0001209191-23-010611
- Filed
- Feb 17, 2023
- Trade date
- Dec 15, 2022
- Filing delay
- 64 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 16, 2022
This filing lists 1 non-derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $6.86K. It was filed 64 days after the trade.
This amendment restates part of 0001209191-22-061755 (filed Dec 16, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Piscitelli DominicCIK 0001695028 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2022 | Common Stock | SSaleDisposed | −2,227 | $3.08F1 | −$6,859.16 | 67,285 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001209191-22-061755 (filed Dec 16, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2022 | Common Stock | MOption exerciseAcquired | +6,041 | $0.00F1 | $0 | 69,512 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2022 | Common Stock | MOption exerciseDisposed | −6,041 | $0.00 | $0 | 12,084 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person.
Referenced by the price of 1 transaction in Table I.